Switching from Pramipexole to Ropinirole: Not Recommended
I strongly advise against switching from pramipexole 1 mg to ropinirole (Requip) 1 mg, as both medications carry similar risks of serious long-term complications, and a simple 1:1 dose conversion is pharmacologically incorrect and potentially harmful. 1, 2
Why This Switch Is Problematic
Both Drugs Are No Longer First-Line Therapy
The most recent 2025 American Academy of Sleep Medicine guidelines and 2026 Mayo Clinic algorithm conditionally recommend against the standard use of both pramipexole and ropinirole due to their high risk of augmentation (paradoxical worsening of symptoms) occurring in 42-70% of patients over 8-10 years 1, 2. Both medications share the same fundamental problems:
- Augmentation risk: 5-7% per year with long-term use
- Impulse control disorders: 6-17% of patients develop compulsive gambling, shopping, or hypersexual behaviors 2
- Similar adverse effect profiles: nausea, orthostatic hypotension, somnolence, hallucinations 3
The Dose Conversion Is Wrong
A 1:1 conversion from pramipexole to ropinirole is pharmacologically incorrect. The evidence shows:
- The appropriate conversion ratio is 1 mg pramipexole to 4 mg ropinirole (1:4 ratio) 4
- Your proposed 1 mg ropinirole dose would represent a massive underdosing (approximately 75% reduction in dopaminergic effect)
- This would likely cause severe symptom breakthrough and potential withdrawal symptoms
Specific Risks of This Switch
If you're considering this switch due to side effects or lack of efficacy:
If experiencing augmentation on pramipexole: Switching to ropinirole will not solve the problem—both drugs cause augmentation at similar rates 1, 2
If experiencing impulse control disorders: Recent 2024 data shows pramipexole may carry inherently higher ICD risk regardless of dose, while ropinirole's ICD risk is more dose-dependent 5. However, both remain problematic.
Withdrawal risk: Abruptly stopping pramipexole can cause severe withdrawal symptoms including fever, confusion, severe muscle stiffness, depression, and anxiety 3
What You Should Do Instead
If You Must Switch Between Dopamine Agonists
Use the correct 1:4 conversion ratio (1 mg pramipexole = 4 mg ropinirole) and perform an overnight switch, which has been shown to be well-tolerated 4. However, this still doesn't address the fundamental problem that both drugs carry similar long-term risks.
Better Alternatives to Consider
Based on current 2025 guidelines, consider transitioning away from dopamine agonists entirely to 1:
- Iron supplementation (if ferritin appropriate): Ferrous sulfate or IV iron formulations (conditional to strong recommendations)
- Alpha-2-delta ligands: Gabapentin or pregabalin (preferred for long-term management)
- Opioids: Extended-release oxycodone (conditional recommendation, moderate certainty)
- Dipyridamole (conditional recommendation)
Critical Warning Signs to Monitor
If you proceed with any dopamine agonist, watch for augmentation symptoms 2:
- Symptoms appearing earlier in the day than when first started
- Need for higher doses to control symptoms
- Increased intensity of symptoms
- Symptoms spreading to arms or other body parts
Under no circumstances should you increase the dopamine agonist dose if these symptoms occur—this worsens augmentation 2.
Bottom Line
Do not perform a 1:1 switch from pramipexole 1 mg to ropinirole 1 mg. If switching between these agents is absolutely necessary, use the 1:4 conversion ratio (requiring 4 mg ropinirole). However, the better approach is to work with your healthcare provider to transition to alternative therapies that don't carry the same augmentation and impulse control disorder risks that plague both pramipexole and ropinirole.